A Critical Re-Evaluation on "Targeting FSP1 Triggers Ferroptosis in Lung Cancer" by Wu et al., Nature 2025; DOI: 10.1038/s41586-025-09710-8

This repository contains a comprehensive critical commentary on the Nature 2025 paper by Wu et al., titled “Targeting FSP1 triggers ferroptosis in lung cancer” (DOI: 10.1038/s41586-025-09710-8). The commentary provides an in-depth, figure-by-figure evaluation of the study’s experimental design, methodological rigor, data interpretation, and overall scientific validity.

Ferroptosis—a regulated, iron-dependent form of cell death driven by lipid peroxidation—has become a major focus in cancer research. The FSP1 (AIFM2)–CoQ10 axis is widely recognized as a critical suppressor of ferroptosis, prompting significant interest in identifying pharmacologic strategies that overcome this protective barrier. Wu et al. propose that a newly developed FSP1 inhibitor induces ferroptosis and inhibits tumor growth in lung cancer models. However, the legitimacy of these claims depends strongly on the robustness of data demonstrating inhibitor specificity, accurate ferroptosis detection, and reproducibility across models.

This commentary provides a rigorous scientific re-evaluation of the evidence presented. Each main figure, Extended Data figure, and Supplementary figure is analyzed in detail, highlighting concerns with biochemical assays, lipidomics methodology, flow cytometry gating, imaging integrity, CRISPR validation, in vivo experiment design, and statistical reporting. Particular attention is given to issues of data transparency, quantification inconsistencies, insufficient rescue experiments, lack of off-target analyses, and overinterpretation of xenograft outcomes.

The critique identifies recurrent problems such as incomplete ferroptosis validation, limited lipid peroxidation profiling, questionable pharmacological specificity of the inhibitor, ambiguous normalization strategies, potential duplication of microscopy panels, and inconsistencies in replicates and statistical treatment. Beyond specific methodological flaws, the commentary addresses broader conceptual issues, including overstated novelty, inadequate engagement with prior literature on GPX4-independent ferroptosis pathways, and uncertainties regarding whether the observed cell death phenotypes represent bona fide ferroptosis rather than mixed or non-specific oxidative stress responses.

By consolidating these detailed observations, the commentary aims to facilitate transparent post-publication peer review, encourage methodological rigor in ferroptosis research, and support reproducibility within the cancer biology community. Ferroptosis remains a rapidly evolving field with profound therapeutic potential; therefore, careful and precise evaluation of new claims is essential to avoid premature conclusions and ensure the reliability of emerging mechanistic insights.

The repository supports researchers, reviewers, and clinicians who require an independent and analytically rigorous assessment of the study’s findings and their implications for ferroptosis-targeting strategies in lung cancer.